Pathologic evaluation of prostatic carcinoma: Critical information for the oncologist

ONCOLOGY

Volumn 10, Issue 4, 1996, Pages 527-534

  Epstein, Jonathan I ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; BLOOD; CANCER INVASION; CANCER STAGING; COLLOID CARCINOMA; DISEASE COURSE; HUMAN; LYMPH NODE METASTASIS; MALE; NEEDLE BIOPSY; NEUROENDOCRINE TUMOR; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; REVIEW; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; BIOPSY, NEEDLE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030116827     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. McNeal JE, Bostwick DG: Intraductal dysplasia: A pie-malignant lesion of the prostate. Hum Pathol 17:64-71, 1986.
2. Epstein JI, Grignon DJ, Humphrey PA. et al: Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 19:873-886, 1995.
3. Keetch D, Humphrey P, Stahl D. et al: Morphometric analysis and clinical follow-up of isolated prostatic intraepithelial neoplasia in needle biopsy of the piostate. J Urol 154:347-351, 1995.
4. Epstein JI: Prostatic intraepithelial neoplasia. adv Anat Pathol 1:123-134, 1994.
5. Hamper UM, Sheth S. Walsh PC. et al: Stage B adenocarcinoma of the prostate: Transrectal US and pathologic peripheral zone lesions. Radiology 180:101-104. 1991.
6. Ronnette BM, CarMichael MJ. Carter HB, et at: Does prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol 150:386-389, 1993.
7. Sakr WA, Haas GP. Cassin BF, et al: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150:379-385, 1993.
8. Ferguson J, Zincke H, Ellison E. et al: Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with T3 carcinoma treated by radical prostatectomy. Urology 44:91-95, 1994.
9. Epstein JI, Walsh PC, CarMichael M. et al: Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer JAMA 271:368-374, 1994
10. Ayala AG, Ro JY, Babaian R, et al: The prostatic capsule: Does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 13:21-27, 1989
11. Villers AA. McNeal JE. Redwine EA, et al: The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol 142:763-768. 1989
12. McNeal JE. Cancer volume and site of origin of adenocarcinoma of the prostate Relationship to local and distant spread Hum Pathol 23:258-266, 1992.
13. Gleason DF, Mellinger GT. and the Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 111:58-64, 1974.
14. 13a. Steinberg D, Sauvageot J, Epstein JI: Correlation of needle biopsy and radical prostatectomy grade in academic and community practice settings. Modern Pathol 9:83 (abstract), 1991.
15. Epstein JI, Pizov G. Walsh PC: Correlation of pathologic findings with progression following radical retropubic prostatectomy Cancer 71:3582-3593, 1993.
16. McNeal JE, Villers AA, Redwine EA, et al: Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66:1225-1233, 1990
17. Epstein JI. PSAP and PSA as immunohistochemical markers. Urol Clin North Am 20.757-770, 1993.
18. Spires SE. Cibull ML, Wood DP, et al: Gleason histologic grading in prostatic carcinoma: Correlation of 18-guage core biopsy with prostatectomy. Arch Pathol Lab Med 118:705-708, 1994.
19. Bostwick DG: Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 18:796-803, 1994
20. Gleason DF. The Veterans Administration Cooperative Urologieal Research Group: Histologic grading and clinical staging of prostatic carcinoma in. Tannenbaum M (ed): Urologic Pathology The Prostate, pp 171-197. Philadelphia, Lea and Febiger, 1977.
21. Oesterling JE, Brendler CB, Epstein JI, et al: Correlation of clinical stage, serum prostatic acid phosphatase. and pre-operative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 138:92-98, 1987.
22. Partin AW, Steinberg GD, Pitcock RV. et al: Use of nuclear morphometry, Gleason histologic scoring, clinical stage and age to predict disease-free survival among patients with prostate cancer. Cancer 70.161-168, 1992.
23. Epstein JI: Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 26.223-229, 1995.
24. Wojno K.I. Fpstein JI: The utility of basal cell specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer: A review of 228 cases. Am J Surg Pathol 19:251-260. 1995
25. Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151:1571-1574, 1994.
26. Partin AW, Yoo J. Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150:110-114, 1993.
27. Bastaeky SI, Walsh PC, Epstein JI: Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 17:336-341, 1993.
28. Adolfsson J: Prognostic Value of deoxyribonucleic acid content in prostate cancer: a review of current results Int J Cancer 58:211-216, 1994.
29. Shankey TV, Kallioniemi OP. Koslowski JM, et al. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cvrometry 14:497-500, 1993.
30. Ross JS, Figge H, Bui HX. et at: Prediction of pathologic stage and post-prostatectomy disease recurrence by DNA ploidy analysis of initial prostatic cancer needle biopsy specimens. Cancer 74 2811-2818, 1994.
31. Cantrell BB, DeKlerk DP, Eggleston JC. et al. Pathological factors that influence prognosis in stage A prostatic cancer: The influence of extent versus grade. J Urol 125:516-520, 1981.
32. Eblc JN, Epstein JI: Stage A carcinoma of the prostate, in Bostwick DG(consulant ed). Roth LM(ed). Pathology the Prostate, Seminal Vesicles, and Male Urethra, pp 61-82. New York. Churchill Livingstone, 1990. Contemporary issues in Surgical Pathology.
33. Gaudin PB. Epstein JI: Adenosis of the prostate Histologic features in transurethral resection specimens. Am J Surg Pathol 18:863-870, 1994.
34. Sgrignoli AR, Walsh PC, Steinberg GD, et al: Prognostic factors in men with stage Dl prostate cancer: Identification of patients less likely to benefit from radical surgery. J Urol 152.1077-1081. 1994.
35. Winkler HZ, Rainwater LM. Myers RP, et al: Stage D1 prostatic adenocarcinoma: Significance of nuclear DNA patterns studied by flow cytometry. Mayo Clin Proc 63:103-112, 1988.
36. Epstein JI, Partin AW, Sauvageot J. et al: Prediction of progression following radical prostateclomy: A mullivanate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20:286-292, 1996.
37. Stamey TA. Villers AA, MeNeal JE, et al: Positive surgical margins at radical prostatectomy Importance of the apical dissection. J Urol 143:1166-1173, 1990.
38. Epslein JI: Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive Am J Surg Pathol 14:626-632, 1990
39. Epstein JI, Carmichael M, Partin AW, et at: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years follow-up. J Urol 149:1478-1481, 1993.
40. Epstein JI: Disorders of the piostate gland. in Steinberg SS (ed). Diagnosis in Surgical Pathology. 2nd Ed. p 1846. New York. Raven Press. 1993
41. Weidner N, Carrol PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate cancer. Am J Pathol 143 401-409, 1993.
42. Cohen RJ, Glezerson G. Haffejee Z, et al: Prostatic carcinoma: Histological factors affecting prognosis. Br J Urol 66:405-410, 1990.
43. Sadasivan R. Morgan R, Jennmgs S. et al Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer J Urol 150:126-131, 1993.
44. Umbas R. Isaacs WB. Bringuiei PP. et al: Decreased E-cadherin expression is associated with poor prognosis in patients, with prostate cancer. Cancer Res 52:5104-5109. 1992
45. Shurbaji MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical detection ot P53 protein as a prognostic indicator in prostate cancer Hum Pathol 26:106-109, 1995.
46. Epstein JI, Lieberman P: Mucinous adenocarcinomas of the prostate gland Am J Surg Pathol 9:299-307, 1985.
47. di Santagnese PA: Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 23:287-296, 1992.
48. Tetu B, Ro JY, Ayala AG, et al Small cell carcinoma of prostate. Part I: A climeopathologic study of 20 cases. Cancer 59:1803-1809, 1987.
49. Epstein JI, Woodruff J. Prostatic carcinomas with endometrioid features: A light microscopic and Immunohistochemical study of ten cases. Cancer 57: 111-119, 1986.
50. Christensen WN, Steinberg WN. Walsh PC, et al: Prostatic duct adenocarcinoma: Findings at radical prostatectomy. Cancer 67:2118-2124. 1991.
51. Little NA. Wiener JS. Walther PJ. et al Squamous cell carcinoma of the prostate: 2 cases of a rare malignancy and review of the literature. J Urol 149:137-139, 1993.